Delivery of a targeted nanocarrier formulated with IVT mRNA encoding IRF5 and IKKβ, induced reversion of the suppressive state of TAMs from a tumor-supporting phenotype towards a phenotype that induced anti-tumor immunity and promoted tumor suppression [102]. The gene discussed is IRF5; the disease is neoplasm.